Identification and validation of novel drug targets in tuberculosis

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3185-3194

  Duncan, Ken ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; 5 CHLOROPYRAZINAMIDE; 6 AZIDO 6 DEOXYTREHALOSE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIMYCOBACTERIAL AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOSERINE; DIHYDRODIPICOLINATE REDUCTASE INHIBITOR; DNA POLYMERASE INHIBITOR; ENZYME INHIBITOR; ETHAMBUTOL; ETHIONAMIDE; ISOCITRATE LYASE INHIBITOR; ISONIAZID; ISONIAZID DERIVATIVE; METHIONINE SULFOXIMINE; MYOINOSITOL 1 PHOSPHATE SYNTHASE INHIBITOR; N GERANYL N (2 ADAMANTYL)ETHANE 1,2 DIAMINE; NITROIMIDAZOLE DERIVATIVE; PYRAZINAMIDE; PYRAZINOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIOLACTOMYCIN; THYMIDINE PHOSPHATE KINASE INHIBITOR; TREHALOSE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL SURVIVAL; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HOST PATHOGEN INTERACTION; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TUBERCULOSIS; VALIDATION PROCESS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; GREAT BRITAIN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 4644349770     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383223     Document Type: Review

References (140)

1. World Health Organisation. Global Tuberculosis Control: Surveillance, Planning Financing. WHO Report 2003. WHO/CDS/TB/2003.316. 2003. Geneva, Switzerland.
2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
3. Espinal MA. The global situation of MDR-TB. Tuberculosis (Edinb) 2003; 83: 44-51.
4. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-8.
5. Duncan K. Progress in TB drug development and what is still needed. Tuberculosis (Edinb) 2003; 83: 201-7.
6. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 983-1009.
7. Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56: 607-16.
8. Maccari R, Ottana R, Monforte F, Vigorita MG. In vitro antimycobacterial activities of 2′-monosubstituted isonicotinohydrazides and their cyanoborane adducts. Antimicrob Agents Chemother 2002; 46: 294-9.
9. Cynamon MH, Speirs RJ, Welch JT. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 1998; 42: 462-3.
10. Seitz LE, Suling WJ, Reynolds RC. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives. J Med Chem 2002; 45: 5604-6.
11. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE, III. Combinatorial lead optimization of [1, 2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2001; 5: 172-87.
12. Ginsburg AS, Grosser JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42.
13. Tuberculosis Research Centre C. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberculosis 2002; 49: 27-38.
14. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-9.
15. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-4.
16. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-6.
17. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-5.
18. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70.
19. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45.
20. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996; 39: 680-5.
21. Stover CK, Warrener P, Van Devanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
22. Global Alliance for TB Drug Development. The Economics of TB Drug Development. Global Alliance for TB Drug Development 2001.
23. Global Alliance for TB Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 2001; 81 Suppl 1: 1-52.
24. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
25. Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-73.
26. Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184: 5479-90.
27. Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003; 100: 7877-82.
28. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.
29. Eiglmeier K, Parkhill J, Honore N, Garnier T, Tekaia F, Telenti A, et al. The decaying genome of Mycobacterium leprae. Lepr Rev 2001; 72: 387-98.
30. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 1999; 96: 12833-8.
31. Betts JC, McLaren A, Lennon MG, Kelly FM, Lukey PT, Blakemore SG, et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin- and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2903-13.
32. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2003; 83: 91-7.
33. Kremer LS, Besra GS. Current status and future development of antitubercular chemotherapy. Expert Opin Investig Drugs 2002; 11: 1033-49.
34. Khasnobis S, Escuyer VE, Chatterjee D. Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin Ther Targets 2002; 6: 21-40.
35. Barry CE, III. Preclinical candidates and targets for tuberculosis therapy. Curr Opin Investig Drugs 2001; 2: 198-201.
36. Besra GS, Brennan PJ. The mycobacterial cell wall: biosynthesis of arabinogalactan and lipoarabinomannan. Biochem Soc Trans 1997; 25: 845-50.
37. Lee RE, Brennan PJ, Besra GS. Mycobacterium tuberculosis cell envelope. Curr Top Microbiol Immunol 1996; 215: 1-27.
38. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001; 55: 139-63.
39. Loebel RO, Shorr E, Richardson HB. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 1933; 26: 167-200.
40. Loebel RO, Shorr E, Richardson HB. The influence of foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 1933; 26: 139-66.
41. Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-77.
42. Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am J Respir Cell Mol Biol 2001; 25: 606-12.
43. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin. Proc Natl Acad Sci USA 2001; 98: 7534-9.
44. Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001; 183: 2672-6.
45. Boon C, Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 2002; 184: 6760-7.
46. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-31.
47. Fisher MA, Plikaytis BB, Shinnick TM. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol 2002; 184: 4025-32.
48. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003, 198: 705-13.
49. McAdam PA, Quan S, Smith DA, Bardarov S, Betts JC, Cook FC, et al. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 2002; 148: 2975-86.
50. Sassetti CM, Boyd DH, Rubin EJ. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci USA 2001; 98: 12712-7.
51. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
52. Banerjee A, Dubnau F, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.
53. Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs WR Jr, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995; 34: 8235-41.
54. Larsen MH, Vilcheze C, Kremer L, Besra GS, Parsons L, Salfinger M, et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002; 46: 453-66.
55. Kremer L, Dover LG, Morbidoni HR, Vilcheze C, Maughan WN, Baulard A, et al. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 2003; 278: 20547-54.
56. Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-10.
57. Parish T, Stoker NG. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 2000; 146: 1969-75.
58. Bardarov S, Bardarov Jr S Jr, Pavelka JM Jr, Sambandamurthy V, Larsen M, Tufariello J, et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 2002; 148: 3007-17.
59. Pelicic V, Jackson M, Reyrat JM, Jacobs WR Jr, Gicquel B, Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1997; 94: 10955-60.
60. Parish T, Lewis J, Stoker NG. Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essentiality. Tuberculosis (Edinb) 2001; 81: 359-64.
61. Parish T, Stoker NG. glnE is an essential gene in Mycobacterium tuberculosis. J Bacteriol 2000; 182: 5715-20.
62. Zahrt TC, Deretic V. An essential two-component signal transduction system in Mycobacterium tuberculosis. J Bacteriol 2000; 182: 3832-8.
63. Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 2002; 148: 3069-77.
64. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I. ideR, An essential gene in Mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 2002; 70: 3371-81.
65. Strych U, Penland RL, Jimenez M, Krause KL, Benedik MJ. Characterization of the alanine racemases from two mycobacteria. FEMS Microbiol Lett 2001; 196: 93-8.
66. Feng Z, Barletta RG. Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 2003; 47: 283-91.
67. Kemp LE, Bond CS, Hunter WN. Structure of 2C-methyl-D-erythritol 2, 4- cyclodiphosphate synthase: an essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development. Proc Natl Acad Sci USA 2002; 99: 6591-6.
68. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996; 93: 11919-24.
69. Escuyer VE, Lety MA, Torrelles JB, Khoo KH, Tang JB, Rithner CD, et al. The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 2001; 276: 48854-62.
70. Lee RE, Brennan PJ, Besra GS. Mycobacterial arabinan biosynthesis: the use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay. Glycobiology 1997; 7: 1121-8.
71. Weston A, Stern RJ, Lee RE, Nassau PM, Monsey D, Martin SL, et al. Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber Lung Dis 1997; 78: 123-31.
72. Sanders DA, Staines AG, McMahon SA, McNeil MR, Whitfield C, Naismith JH. UDP-galactopyranose mutase has a novel structure and mechanism. Nat Struct Biol 2001; 8: 858-63.
73. Pan F, Jackson M, Ma Y, McNeil M. Cell wall core galactofuran synthesis is essential for growth of mycobacteria. J Bacteriol 2001; 183: 3991-8.
74. Ma Y, Pan F, McNeil M. Formation of dTDP-rhamnose is essential for growth of mycobacteria. J Bacteriol 2002; 184: 3392-5.
75. Kordulakova J, Gilleron M, Mikusova K, Puzo G, Brennan PJ, Gicquel B, et al. Definition of the first mannosylation step in phosphatidylinositol mannoside synthesis. PimA is essential for growth of mycobacteria. J Biol Chem 2002; 277: 31335-44.
76. Jackson M, Crick DC, Brennan PJ. Phosphatidylinositol is an essential phospholipid of mycobacteria. J Biol Chem 2000; 275: 30092-9.
77. Schaeffer ML, Khoo KH, Besra GS, Chatterjee D, Brennan PJ, Belisle JT, et al. The pimB gene of Mycobacterium tuberculosis encodes a mannosyltransferase involved in lipoarabinomannan biosynthesis. J Biol Chem 1999; 274: 31625-31.
78. Kremer L, Gurcha SS, Bifani P, Hitchen PG, Baulard A, Morris HR, et al. Characterization of a putative α-mannosyltransferase involved in phosphatidylinositol trimannoside biosynthesis in Mycobacterium tuberculosis. Biochem J 2002; 363: 437-47.
79. Norman RA, McAlister MS, Murray-Rust J, Movahedzadeh F, Stoker NG, McDonald NQ. Crystal structure of inositol 1-phosphate synthase from Mycobacterium tuberculosis, a key enzyme in phosphatidylinositol synthesis. Structure 2002; 10: 393-402.
80. Heath RJ, White SW, Rock CO. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 2001; 40: 467-97.
81. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR, Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000; 6: 1043-7.
82. Boshoff HI, Mizrahi V, Barry CE, III. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 2002; 184: 2167-72.
83. Kremer L, Nampoothiri KM, Lesjean S, Dover LG, Graham S, Betts J, et al. Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA:AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II. J Biol Chem 2001; 276: 27967-74.
84. Choi KH, Kremer L, Besra GS, Rock CO. Identification and substrate specificity of β-ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J Biol Chem 2000; 275: 28201-7.
85. Scarsdale JN, Kazanina G, He X, Reynolds KA, Wright HT. Crystal structure of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase III. J Biol Chem 2001; 276: 20516-22.
86. Banerjee A, Sugantino M, Sacchettini JC, Jacobs WR, Jr. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 1998; 144: 2697-704.
87. Marrakchi H, Ducasse S, Labesse G, Montrozier H, Margeat E, Emorine L, et al. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology 2002; 148: 951-60.
88. Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 2000; 182: 4059-67.
89. Marrakchi H, Laneelle G, Quemard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 2000; 146: 289-96.
90. Kremer L, Douglas JD, Baulard AR, Morehouse C, Guy MR, Alland D, et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000; 275: 16857-64.
91. Schaeffer ML, Agnihotri G, Volker C, Kallender H, Brennan PJ, Lonsdale JT. Purification and biochemical characterization of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthases KasA and KasB. J Biol Chem 2001; 276: 47029-37.
92. Slayden RA, Barry CE, III. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002; 82: 149-60.
93. Cohen-Gonsaud M, Ducasse S, Hoh F, Zerbib D, Labesse G, Quemard A. Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis. J Mol Biol 2002; 320: 249-61.
94. Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Jr., Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279: 98-102.
95. Rozwarski DA, Vilcheze C, Sugantino M, Bittman R, Sacchettini JC. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 1999; 274: 15582-9.
96. Glickman MS, Cox JS, Jacobs WR, Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5: 717-27.
97. Glickman MS. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal cyclopropane synthase of the α-mycolic acid. J Biol Chem 2003; 278: 7844-9.
98. Huang CC, Smith CV, Glickman MS, Jacobs WR Jr, Sacchettini JC. Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J Biol Chem 2002; 277: 11559-69.
99. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276: 1420-22.
100. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276: 1420-1422.
101. Jackson M, Raynaud C, Laneelle MA, Guilhot C, Laurent-Winter C, Ensergueix D, et al. Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol Microbiol 1999; 31: 1573-87.
102. Harth G, Horwitz MA, Tabatadze D, Zamecnik PC. Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology. Proc Natl Acad Sci USA 2002; 99: 15614-9.
103. Anderson DH, Harth G, Horwitz MA, Eisenberg D. An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. J Mol Biol 2001; 307: 671-81.
104. Magalhaes ML, Pereira CP, Basso LA, Santos DS. Cloning and expression of functional shikimate dehydrogenase (EC 1.1.1.25) from Mycobacterium tuberculosis H37Rv. Protein Expr Purif 2002; 26: 59-64.
105. Oliveira JS, Pinto CA, Basso LA, Santos DS. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis. Protein Expr Purif 2001; 22: 430-5.
106. Gourley DG, Coggins JR, Isaacs NW, Moore JD, Charles IG, Hawkins AR. Crystallization of a type II dehydroquinase from Mycobacterium tuberculosis. J Mol Biol 1994; 241: 488-91.
107. Evans LD, Roszak AW, Noble LJ, Robinson DA, Chalk PA, Matthews JL, et al. Specificity of substrate recognition by type II dehydroquinases as revealed by binding of polyanions. FEBS Lett 2002; 530: 24-30.
108. Gu Y, Reshetnikova L, Li Y, Wu Y, Yan H, Singh S, et al. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of the LID domain in catalysis. J Mol Biol 2002; 319: 779-89.
109. Pavelka MS Jr, Jacobs WR Jr. Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J Bacteriol 1999; 181: 4780-9.
110. Gokulan K, Rupp B, Pavelka MS Jr, Jacobs WR Jr, Sacchettini JC. Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacterial lysine biosynthesis. J Biol Chem 2003; 278: 18588-96.
111. Paiva AM, Vanderwall DE, Blanchard JS, Kozarich JW, Williamson JM, Kelly TM. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. Biochim Biophys Acta 2001; 1545: 67-77.
112. Harth G, Clemens DL, Horwitz MA. Glutamine synthetase of Mycobacterium tuberculosis: extracellular release and characterization of its enzymatic activity. Proe Natl Acad Sci USA 1994; 91: 9342-6.
113. Harth G, Zamecnik PC, Tang JY, Tabatadze D, Horwitz MA. Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication. Proc Natl Acad Sci USA 2000; 97: 418-23.
114. Tullius MV, Harth G, Horwitz MA. Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Infect Immun 2003; 71: 3927-36.
115. Harth G, Horwitz MA. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets. J Exp Med 1999; 189: 1425-36.
116. Harth G, Horwitz MA. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo. Infect Immun 2003; 71: 456-64.
117. Gerum AB, Ulmer JE, Jacobus DP, Jensen NP, Sherman DR, Sibley CH. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 2002; 46: 3362-9.
118. Miesel L, Weisbrod TR, Marcinkeviciene JA, Bittman R, Jacobs WR Jr. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol 1998; 180: 2459-67.
119. Sharma V, Grubmeyer C, Sacchettini JC. Crystal structure of quinolinic acid phosphoribosyltransferase from Mycobacterium tuberculosis: a potential TB drug target. Structure 1998; 6: 1587-99.
120. Bellinzoni M, De Rossi E, Branzoni M, Milano A, Peverali FA, Rizzi M, et al. Heterologous expression, purification, and enzymatic activity of Mycobacterium tuberculosis NAD(+) synthetase. Protein Expr Purif 2002; 25: 547-57.
121. Li, I, Munier-Lehmann H, Gilles AM, Barzu O, Delarue M. X-ray structure of TMP kinase from Mycobacterium tuberculosis complexed with TMP at 1.95 Å resolution. J Mol Biol 2001; 311: 87-100.
122. Haouz A, Vanheusden V, Munier-Lehmann H, Froeyen M, Herdewijn P, Van Calenbergh S, et al. Enzymatic and structural analysis of inhibitors designed against Mycobacterium tuberculosis thymidylate kinase. New insights into the phosphoryl transfer mechanism. J Biol Chem 2003; 278: 4963-71.
123. Vanheusden V, Munier-Lehmann H, Pochet S, Herdewijn P, Van Calenbergh S. Synthesis and evaluation of thymidine-5′ -O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg Med Chem Lett 2002; 12: 2695-8.
124. Boshoff HI, Reed MB, Barry CE III, Mizrahi V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 2003; 113: 183-93.
125. McKinney JD, Honer Zu BK, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-8.
126. Honer Zu BK, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999; 181: 7161-7.
127. Sharma V, Sharma S, Hoener zu BK, McKinney JD, Russell DG, Jacobs WR Jr, et al. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 2000; 7: 663-8.
128. Smith CV, Huang CC, Miczak A, Russell DG, Sacchettini JC, Honer Zu BK. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 2003; 278: 1735-43.
129. Av-Gay Y, Everett M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol 2000; 8: 238-44.
130. Drews SJ, Hung F, Av-Gay Y. A protein kinase inhibitor as an antimycobacterial agent. FEMS Microbiol Lett 2001; 205: 369-74.
131. Ortiz-Lombardia M, Pompeo F, Boitel B, Alzari PM. Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis. J Biol Chem 2003; 278. 13094-100.
132. Buchmeier NA, Newton GL, Koledin T, Fahey RC. Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics. Mol Microbiol 2003; 47: 1723-32.
133. Bellamine A, Mangla AT, Nes WD, Waterman MR. Characterization and catalytic properties of the sterol 14 α-demethylase from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1999; 96: 8937-42.
134. Guardiola-Diaz HM, Foster LA, Mushrush D, Vaz AD. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem Pharmacol 2001; 61: 1463-70.
135. McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K, Kieser T, et al. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 2002; 148: 2937-49.
136. Jackson CJ, Lamb DC, Marczylo TH, Parker JE, Manning NL, Kelly DE, et al. Conservation and cloning of CYP51: a sterol 14 α-demethylase from Mycobacterium smegmatis. Biochem Biophys Res Commun 2003; 301: 558-63.
137. Leys D, Mowat CG, McLean KJ, Richmond A, Chapman SK, Walkinshaw MD, et al. Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 Å reveals novel features of cytochrome P450. J Biol Chem 2003, 278: 5141-7.
138. Nagaraja V, Sikder D, Jain P. DNA topoisomerase I from mycobacteria-a potential drug target. Curr Pharm Design 2002; 8(22): 1995-2007.
139. Taylor PC. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Design 2003; 9(14): 1095-106.
140. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82.